COMPOUND W

Main information

  • Trade name:
  • COMPOUND W
  • Dosage:
  • 17.0%w/w %w/w
  • Pharmaceutical form:
  • Cutaneous Solution
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • COMPOUND W
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0618/043/001
  • Authorization date:
  • 01-04-1998
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

CompoundWLiquidWartRemover

2QUALITATIVEANDQUANTITATIVECOMPOSITION

SalicylicAcid17.0%w/w.

Forexcipients,see6.1.

3PHARMACEUTICALFORM

CutaneousSolution.

Faintlyyellowviscouscutaneoussolution.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Asakeratolyticfortreatmentofwartsandverrucae

4.2Posologyandmethodofadministration

Adultsandchildrenover6yearsofage:

Gentlyrubthehardskinfromthesurfaceofthewartwithapumicestoneoremeryboard.Applytowartonedropata

timewithdropper-roduntilwartiscovered.Allowtodrycompletely.Avoidsurroundingskin.Repeatapplication

daily,withregularwashing,foruptofourweeks.

4.3Contraindications

DonotuseCompoundWLiquidWartRemoveronmoles,birthmarks,genitalorfacialwarts.

Nottobeusedonchildrenunder6yearsexceptonmedicaladvice .

4.4Specialwarningsandprecautionsforuse

Ifthereisdoubtastothediagnosisconsultthedoctor.

Patientswithdiabetesshouldconsulttheirdoctoraboutfootproblems.

Avoidcontactwiththeeyes,mouthormucousmembranes.

Donotapplytohealthyskinorskinwhichisinflamedorbroken.IfCompoundWLiquidWartRemovertouches

healthyskin,washoffimmediatelywithplentyofwater.

Ifthereisnoimprovement,oraggravationofthecondition,thedoctorshouldbeconsulted.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 01/03/2010 CRN 2078998 page number: 1

Forexternaluseonly

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Nonestated.

4.6Pregnancyandlactation

Nocontraindicationsknown.

4.7Effectsonabilitytodriveandusemachines

Nonestated

4.8Undesirableeffects

Noneknown

4.9Overdose

Noneprobable

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Salicylicacidfacilitatesdesquamationbysolubilisingtheintercellularcementthatbindsscalesinthestratumcorneum

therebylooseningthekeratin.

5.2Pharmacokineticproperties

Salicylicacidcanbeabsorbedthroughtheskin.Itisexcretedunchangedintheurine.

5.3Preclinicalsafetydata

Notapplicable

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Acetone

IndustrialMethylatedSpirits99%

Procylin(NitrocelluloseDHM10/25)

CastorOil

6.2Incompatibilities

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 01/03/2010 CRN 2078998 page number: 2

6.3ShelfLife

Theshelflifeexpirydateofthisproductshallnotexceed5yearsfromthedateofitsmanufacture.

6.4Specialprecautionsforstorage

Donotstoreabove25°C.

6.5Natureandcontentsofcontainer

Glassbottlewithscrewthreadedplasticcapandplasticapplicatorcontaining6.5mlofproduct.

6.6Specialprecautionsfordisposalandotherhandling

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

SetonProductsLtd.,

TubitonHouse,

OldhamOL13HS,

UnitedKingdom.

8MARKETINGAUTHORISATIONNUMBER

PA0618/043/001

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:01April1983

Dateoflastrenewal: 01April2003

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 01/03/2010 CRN 2078998 page number: 3